Igor Puzanov, MD
Enriched profileSenior Vice President, Clinical Investigation at Roswell Park Comprehensive Cancer Center; Director of the Center for Early Phase Clinical Trials; Chief of the Melanoma Section in the Department of Medicine · Roswell Park Comprehensive Cancer Center
Igor Puzanov is Senior Vice President, Clinical Investigation at Roswell Park Comprehensive Cancer Center; Director of the Center for Early Phase Clinical Trials; Chief of the Melanoma Section in the Department of Medicine at Roswell Park Comprehensive Cancer Center. OpenAlex indexes 683 publications with 56,731 citations (h-index 91); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 19 Oct 2026
Overview
Updated 19 Oct 2026
Igor Puzanov, MD, is Senior Vice President, Clinical Investigation at Roswell Park Comprehensive Cancer Center. The public record shows 683 publications with 56,731 citations (h-index 91), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 11 companies, 3 NIH-funded awards (2020–2025).
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 19 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 266.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 19 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Sponsor: Nested Therapeutics, Inc
- Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Sponsor: Roswell Park Cancer Institute
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Sponsor: Roswell Park Cancer Institute
Industry payments
Updated 19 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Apellis Pharmaceuticals, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20252 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
100%l-Thyroxine100%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 19 Oct 2026
3 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- Network Lead Academic Participating Site Grant from the Roswell Park Cancer Institute
Roswell Park Cancer Institute Corp
FY2025$305,626UG1CA233191
Congress activity
Updated 19 Oct 2026
139 congress contributions (2006–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 2058: Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 19 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.
Journal for immunotherapy of cancer
Article2026 - Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.
Nature communications
Article2025 - Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer.
Journal for immunotherapy of cancer
Article2025 - Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
Nature medicine
Article2025 - Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications.
Journal for immunotherapy of cancer
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Inhibition of Mutated, Activated BRAF in Metastatic MelanomaArticle3,564 citations2010
- 03Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsArticle2,810 citations2012
- 04Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaArticle2,639 citations2015
- 05Fulminant Myocarditis with Combination Immune Checkpoint BlockadeArticle2,292 citations2016
Network
Updated 19 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 19 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/igor-puzanov-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
broadcastmed.com/9753/participant/igor-puzanov-md-msci-facp
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →broadcastmed.com ↗ - Other
roswellpark.org/cancertalk/201610/meet-teamroswell-dr-igor-puzanov
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →roswellpark.org ↗ - Other
roswellpark.org/igor-puzanov
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →roswellpark.org ↗ - Other
roswellpark.org/media/news/roswell-parks-dr-igor-puzanov-honored-his-many-contributions-melanoma-research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 19 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Editorial & leadership roles
journal and society appointments- Fellow
American College of Physicians
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗ - Member
American Society of Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗ - Member
Society of Immunotherapy in Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗ - Member
American Association for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗ - Member
Society of Melanoma Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
Secondary affiliations
appointments beyond the home institution- Professor of Oncology
Roswell Park Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗ - Professor of Medicine
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip McCarthy, MD
Roswell Park Comprehensive Cancer Center
Saby George, MD
Roswell Park Comprehensive Cancer Center
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center
Renuka Iyer, MD
Roswell Park Comprehensive Cancer Center
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Kevin Brown, MD
National Cancer Institute